AFIB News and Press, Acutus Medical Inc. From 03/16/23

2023-03-16 16:03:30 ET Acutus Medical press release ( NASDAQ: AFIB ): Q4 GAAP EPS of $0.41 beats by $1.12 . Revenue of $5M (+14.7% Y/Y) beats by $0.45M . Non-GAAP operating expenses were $13.9 million for the fourth quarter of 2022 compared with $21.4 million i...

CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quar...

CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 202...

Summary Stereotaxis, Inc. stock fell in 2022 because of new product delays and weak new orders. These delays and disappointing new orders were caused by macro headwinds that are abating. There are many catalysts in 2023. The Magic catheter getting the CE Mark should turn investor sentim...

NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference wil...

CARLSBAD, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced results from the AcQForce Flutter Study “AcQForce F...

Summary Acutus Medical reported Q3 2022 financial results on November 10, 2022. The firm is commercializing cardiac ablation, mapping and other related tools in the U.S. and Europe. AFIB has downsized its commercial force and is focusing its efforts on existing customers. I don'...

Acutus Medical ( NASDAQ: AFIB ) sees Q4 2022 revenue of ~$4.7M-$4.9M vs. consensus of $4.16M compared to $4.4M in the Q4 of 2021. Excluding the proceeds associated with milestones from the left-heart access portfolio sale to Medtronic, the company expects cash burn to decline ...

CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited resul...

CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled &#x...